<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45075">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01716026</url>
  </required_header>
  <id_info>
    <org_study_id>IOBA-04-2012</org_study_id>
    <nct_id>NCT01716026</nct_id>
  </id_info>
  <brief_title>Initial Treatment With Bevacizumab in Choroidal Neovascularization Associated to High Myopia</brief_title>
  <acronym>BENEMCOR</acronym>
  <official_title>Establishment of the Initial Protocol With Intravitreal Bevacizumab for the Treatment of Choroidal Neovascularization Associated With High Myopia:3 vs 1.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Universitario de Oftalmobiología Aplicada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Universitario de Oftalmobiología Aplicada</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to determine wether the initial protocol in the treatment of
      subfoveal choroidal neovascularization associated to High Myopia with bevacizumab
      intravitreal injections is more effective when using 3 doses vs using 1 single dose in the
      load period
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Early Treatment Diabetic Retinopathy Study (ETDRS) Best corrected visual acuity</measure>
    <time_frame>1 Year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Differences in best corrected visual acuity in the exit visit compared to the one obtained at screening visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal thickness</measure>
    <time_frame>1 Year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Retinal thickness assessed by Spectral Domain Optical Coherence Tomography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of total injections during study</measure>
    <time_frame>1 Year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total count of bevacizumab intravitreal injections during the whole study</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Choroidal Subfoveal/Juxtafoveal Neovascularization in High Myopia</condition>
  <arm_group>
    <arm_group_label>3 Month Load with 9 month p.r.n.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 Monthly bevacizumab injections with 9 p.r.n. monthly doses if patient meets the treatment criteria for each monthly visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Dose Load Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose treatment with bevacizumab, followed by 2 sham injections if conditions are met in the months 2 and 3, and followed with bevacizumab monthly p.r.n. as per protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevazizumab intravitreal injection</intervention_name>
    <description>Intravitreal injection of bevacizumab</description>
    <arm_group_label>3 Month Load with 9 month p.r.n.</arm_group_label>
    <arm_group_label>Single Dose Load Phase</arm_group_label>
    <other_name>Avastin Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active subfoveal/juxtafoveal choroidal neovascularization in high myopia confirmed by
             Fundus Fluorescein angiography and Optical Coherence Tomography

          -  Best corrected visual acuity loss with less than 6 months of evolution, caused mainly
             by the neovascular lesion (based in investigator´s criteria)

          -  No atrophy or fibrotic component that may prevent visual acuity improvement

          -  Patients previously treated with Photodynamic Therapy are allowed to participate in
             this study

          -  Signed informed consent

          -  Signed data protection consent

          -  Negative pregnancy test in potential childbearing women at screening, with accepted
             contraceptive method during the whole study

        Exclusion Criteria:

          -  Previous vitreous surgery in study eye

          -  Tractional maculopathy or epiretinal membrane found in Optical Coherence Tomography

          -  Media opacities that may prevent correct fundus assessment

          -  Lack of posterior capsule integrity in pseudophakic patients

          -  Patients with great possibilities of not being able to attend to study visits /
             follow visit procedures  (investigator´s criteria)

          -  Patients previously treated with intravitreal antiangiogenic injections
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Maria Ruiz-Moreno, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Castilla-La Mancha</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose Maria Ruiz-Moreno, MD, PhD</last_name>
    <phone>610435999</phone>
    <email>jm.ruiz@umh.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Isabel Lopez-Galvez, MD, PhD</last_name>
    <phone>34 983184734</phone>
    <email>maribel@ioba.med.uva.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHUS - Fundacion IDICHUS</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>La Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ramon Gomez-Ulla, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alfredo Garcia Layana, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Albacete</name>
      <address>
        <city>Albacete</city>
        <zip>02006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jose Maria Ruiz-Moreno, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juan Donate, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marta Suarez de Figueroa, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofia</name>
      <address>
        <city>Murcia</city>
        <zip>30100</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Inmaculada Selles, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antonio Piñero Bustamante, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eduardo Esteban, Gonzalez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Enrique Cervera Taulet, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IOBA - Instituto Universitario de Oftalmobiologia Aplicada</name>
      <address>
        <city>Valladolid</city>
        <zip>47011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria Isabel Lopez-Galvez, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Rio Hortega</name>
      <address>
        <city>Valladolid</city>
        <zip>47012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Javier Montero Moreno, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 18, 2014</lastchanged_date>
  <firstreceived_date>October 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high myopia</keyword>
  <keyword>choroidal neovascularization</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Myopia</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
